S4920 Acneiform Eruption Following Transition From Intravenous to Subcutaneous Vedolizumab Injection in a Patient With Crohn’s Disease

作者
H Raj,Satya Kastuar,Jhuli Patel
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
卷期号:120 (10S2): S1050-S1050 被引量:1
标识
DOI:10.14309/01.ajg.0001147140.18166.99
摘要

Introduction: Vedolizumab, an integrin antagonist that inhibits T-cell migration to the gastrointestinal tract, is effective in managing ulcerative colitis and Crohn’s disease. While its intravenous formulation has a well-established safety profile, data on adverse effects following a switch to the subcutaneous (SC) formulation remain limited. Here, we present the first reported case of an acneiform reaction following the transition from intravenous to subcutaneous vedolizumab in a patient with Crohn's disease. Case Description/Methods: A 72-year-old White man with a history of Crohn’s disease and congenital neutropenia presented with a new-onset facial rash. He was diagnosed with Crohn's disease in 2009 and had been managed with mesalamine, which he discontinued in 2021 in an attempt at conservative management. In 2024, due to worsening symptoms of diarrhea and abdominal pain, a colonoscopy and computed tomography enterography were performed. This revealed an active inflammation in the distal ileum. Vedolizumab therapy was initiated with intravenous induction doses at weeks 0 and 2. It was switched to SC injection at week 6 for patient convenience. One day after the first SC dose, the patient developed a facial rash. On examination, erythematous papules and pustules were noted over the face. Dermatological evaluation confirmed an acneiform eruption likely secondary to vedolizumab. Treatment with oral doxycycline, topical clindamycin, and hydroxyzine led to partial resolution within 2 weeks. The rash recurred following the next SC dose, prompting discontinuation of Vedolizumab. Complete resolution occurred after an 8-week course of oral and topical antibiotics. Discussion: Vedolizumab targets the α4β7 integrin, blocking its interaction with mucosal addressin cell adhesion molecule-1 in the gastrointestinal tract. Dermatological reactions have been reported in fewer than 5% of patients receiving vedolizumab. This case highlights a possible formulation-specific immune-mediated skin reaction. While the exact mechanism is unclear, α4β7 expression on epidermotropic T cells may play a role. The pharmacokinetics of SC vedolizumab have also been reported to cause higher drug exposure and more stable trough levels. Management involves withdrawal of the offending agent and symptomatic treatment. Early recognition of this uncommon reaction can prevent prolonged discomfort and allow alternative strategies for the continued management of inflammatory bowel disease. This abstract was prepared with the assistance of a generative AI tool.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无心完成签到,获得积分10
刚刚
刚刚
努力TOP完成签到 ,获得积分10
刚刚
刚刚
追寻澜完成签到,获得积分10
刚刚
pp完成签到,获得积分10
1秒前
1秒前
隐形曼青的应助被byejack采纳,获得10
1秒前
suha完成签到,获得积分10
1秒前
hhh完成签到 ,获得积分10
1秒前
csy发布了新的文献求助10
1秒前
宁不惜完成签到,获得积分10
1秒前
nature通行证完成签到,获得积分10
2秒前
sky发布了新的文献求助10
2秒前
Daaz完成签到,获得积分10
2秒前
淄博烧烤完成签到,获得积分20
2秒前
2秒前
TT完成签到,获得积分10
2秒前
李老师完成签到,获得积分10
2秒前
孝顺的如南完成签到,获得积分20
2秒前
机灵花生完成签到,获得积分10
3秒前
Caicai发布了新的文献求助10
3秒前
认真向梦完成签到,获得积分10
3秒前
wjw完成签到,获得积分10
3秒前
3秒前
4秒前
一tiao小于完成签到,获得积分10
4秒前
Sam十九完成签到,获得积分10
4秒前
4秒前
yu完成签到 ,获得积分0
4秒前
ke完成签到,获得积分10
4秒前
goodjob32完成签到,获得积分10
5秒前
yy完成签到,获得积分10
5秒前
杜青完成签到,获得积分10
5秒前
TinLi的应助被369ninja采纳,获得10
5秒前
5秒前
隐形曼青的应助被Michael_li采纳,获得10
5秒前
轻松的元瑶完成签到,获得积分10
5秒前
文章多多完成签到,获得积分10
5秒前
神勇萧发布了新的文献求助10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180189
求助须知:如何正确求助?哪些是违规求助? 9570320
关于积分的说明 21810161
捐赠科研通 7776320
什么是DOI,文献DOI怎么找? 3433267
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039